Mood and pain responses to repeat dose intramuscular ketamine in a depressed patient with advanced cancer

Journal of Palliative Medicine

Volumn 15, Issue 4, 2012, Pages 400-403

  Zanicotti, Claudia Grott ^a   Perez, David ^a   Glue, Paul ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; GEMCITABINE; KETAMINE; METHADONE; QUETIAPINE; VENLAFAXINE;

ADULT; ALCOHOLISM; ANALGESIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; DEPERSONALIZATION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG ABUSE; DYSTHYMIA; EMOTIONAL STRESS; FEMALE; GUILT; HUMAN; IRRITABILITY; MAJOR DEPRESSION; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MOOD; MOTOR DYSFUNCTION; OVARY CARCINOMA; PAIN ASSESSMENT; SLEEP DISORDER; TREATMENT OUTCOME; TREATMENT RESPONSE; VISCERAL PAIN;

ADULT; ANESTHETICS, DISSOCIATIVE; DEPRESSIVE DISORDER, MAJOR; DISEASE PROGRESSION; DYSTHYMIC DISORDER; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; KETAMINE; NEOPLASMS; PAIN; PAIN MEASUREMENT; PSYCHOMETRICS; QUALITY OF LIFE; STATISTICS AS TOPIC;

EID: 84859790090     PISSN: 10966218     EISSN: 15577740     Source Type: Journal    
DOI: 10.1089/jpm.2011.0314     Document Type: Article

References (24)

1. Hotopf M, Chidgey J, Addington-Hall J, Ly KL: Depression in adVanced disease: A systematic review. Part 1. Prevalence and case finding. J Palliat Med 2002;16:81-97. (Pubitemid 34326513)
2. Mitchell AJ, Chan M, Bhatti H, Halton M, Grassi L, Johansen C, Meader N: Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: A meta-analysis of 94 interviewbased studies. Lancet Oncol 2011;12:160-174.
3. Salvo N, Zeng L, Zhang L, Leung M, Khan L, Presutti R, Nguyen J, Holden L, Culleton S, Chow E: Frequency of reporting and predictive factors for anxiety and depression in patients with adVanced cancer. Clin Oncol (R Coll Radiol) 2011;6:in press.
4. Hashimoto K: Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res Rev 2009;61:105-123.
5. Zarate C Jr, Machado-Vieira R, Henter I, Ibrahim L, Diazgranados N, Salvadore G: Glutamatergic modulators: The future of treating mood disorders? Harv Rev Psychiatry 2010;18:293-303.
6. Machado-Vieira R, Yuan P, Brutsche N, Diazgranados N, Luckenbaugh D, Manji HK, Zarate CA Jr: Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist. J Clin Psychiatry 2009;70: 1662-1666.
7. Mercadante S, Porzio G, Gebbia V: Spinal analgesia for adVanced cancer patients: An update. Crit Rev Oncol Hematol 2011;16:in press.
8. Montgomery SA, Asberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134: 382-389. (Pubitemid 9136500)
9. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders (4th ed). Washington, DC, 2000.
10. Harich, J: The comparative pain scale. www.tipna.org/info/ documents/ComparativePainScale.htm. (Last acessed 10/ 03/2011.
11. Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, Kammerer WA, Quezado Z, Luckenbaugh DA, Salvadore G, Machado-Vieira R, Manji HK, Zarate CA Jr: A randomized add-on trial of an N-methyl-Daspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 2010;67:793-802.
12. Bjelland I, Dahl AA, Haug TT, Neckelmann D: The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res 2002;52:69-77. (Pubitemid 34192886)
13. Zigmond AS, Snaith RP: The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361-370. (Pubitemid 13098606)
14. Kissane DW, Wein S, Love A, Lee XQ, Kee PL, Clarke DM: The Demoralization Scale: A report of its development and preliminary validation. J Palliat Care 2004;20:269-276. (Pubitemid 40137570)
15. Stefanczyk-Sapieha L, Oneschuk D, Demas M: Intravenous ketamine "burst" for refractory depression in a patient with adVanced cancer. J Palliat Med 2008;11:1268-1271.
16. Hawley CJ, Gale TM, Sivakumaran T: Defining remission by cut off score on the MADRS: Selecting the optimal value. J Affect Disord 2002;72:177-184. (Pubitemid 35012022)
17. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK: A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006;63:856-864. (Pubitemid 44188478)
18. Aan het Rot M, Collins KA, Murrough JW, Perez AM, Reich DL, Charney DS, Mathew SJ: Safety and efficacy of repeateddose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 2010;67:139-145.
19. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH: Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000;47:351-354. (Pubitemid 30109248)
20. Messer MM, Haller IV: Maintenance ketamine treatment produces long-term recovery from depression. Primary Psychiatry 2010;17:48-50.
21. Glue P, Gulati A, Le Nedelec M, Duffull F: Dose- and exposure-response to ketamine in depression. Biol Psychiatry 2011;7:in press.
22. Duman RS, Li N, Liu RJ, Duric V, Aghajanian G: Signaling pathways underlying the rapid antidepressan actions of ketamine. Neuropharmacology 2012;62:35-41.
23. Liebrenz M, Stohler R, Borgeat A: Repeated intravenous ketamine therapy in a patient with treatment-resistant major depression. World J Biol Psychiatry 2009;10:640-643.
24. Phelps LE, Brutsche N, Moral JR, Luckenbaugh DA, Manji HK, Zarate CA Jr: Family history of alcohol dependence and initial antidepressant response to an NMDA antagonist. Biol Psychiatry 2009;65:181-184.